Rhabdomyolysis and Simvastatin
Authors: J.P. Deslypere, A. Vermeulen
Journal: Annals of Internal Medicine (1991)

Letters15 February 1991Rhabdomyolysis and SimvastatinJ.P. Deslypere, MD, A. Vermeulen, MDJ.P. Deslypere, MDSearch for more papers by this author, A. Vermeulen, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-4-342_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors:Lovastatin, a new cholesterol-lowering drug inhibiting the activity of 3-hydroxy-3 methylglutaryl-CoA reductase can cause myositis and elevation in creatine kinase levels in a small proportion (< 0.5%) of patients (1-4). Severe muscle damage and acute renal failure have been described in association with lovastatin use. The incidence of these outcomes appears to be greatly increased by concomitant therapy with gemfibrozil and nicotinic acid and even more by immunosuppressive therapy including therapy with cyclosporine (1-4).These complications have not been described in association with the use of simvastatin (Zocor, Merck Sharp & Dohme, West Point, Pennsylvania), another more recently...References1. Tobert J. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988;318:48. MedlineGoogle Scholar2. EastAlivizatorGrundyJonesFarmer CPSPJ. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988;318:47-8. CrossrefMedlineGoogle Scholar3. NormanIllingworthMunsonHosenpud DDJJ. Myolysis and acute renal failure in a heart transplant recipient receiving lovastatin. N Engl J Med. 1988;318:46-7. CrossrefMedlineGoogle Scholar4. Tobert J. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University Hospital B-9000 Ghent Belgium PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAmyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA’s Adverse Event Reporting SystemSimvastatinNecrotizing MyopathiesDrug-Induced DermatomyositisLIPID – REGULATING DRUGSActivity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestationsCYP2D6*4 polymorphism is associated with statin-induced muscle effectsStatin-induced rhabdomyolysisSimvastatinHMG-CoA Reductase Inhibitors (statins) might Cause High Elevations of Creatine Phosphokinase (CK) in Patients with Unnoticed HypothyroidismToxic MyopathiesPharmacokinetics and Lipid-Lowering Effect of Fluvastatin in Hypercholesterolaemic Patients on Maintenance HaemodialysisEffectiveness of Statin-Gemfibrozil Combination Therapy in Patients With Mixed Hyperlipidemia: Experience of a Community Lipid Clinic and Safety Review From the LiteratureChapter 32 Toxic myopathiesAcquired MyopathiesNeuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophyRhabdomyolysis and HMG-CoA Reductase InhibitorsStatin—Fibrate Combination TherapyFatal rhabdomyolysis associated with simvastatin in a renal transplant patientHMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, Trk, and morphological differentiation with fatal outcome in PC12 cellsAcute Renal Failure After Cardiopulmonary Bypass: A Possible Association With Drugs of the Fibrate GroupCombined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering interventionEffect of simvastatin on the lipid profile of hemodialysis patientsSimvastatin and Rhabdomyolysis — A Case Report and Brief ReviewSecurity and Maximal Tolerated Doses of Fluvastatin In Pediatric Cancer PatientsEffects of Lipid-Lowering Drugs on Left Ventricular Function and Exercise Tolerance in Dyslipidemic Coronary PatientsDermatomyositis and DrugsEFFICACY AND MUSCLE SAFETY OF FLUVASTATIN IN CYCLOSPORINE-TREATED CARDIAC AND RENAL TRANSPLANT RECIPIENTSMetabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant PatientsGrapefruit juice–drug interactionsLong-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined HyperlipidemiaTOXIC MYOPATHIESAction of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscleDifferential Effects of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors on the Development of Myopathy in Young RatsDermatomyositis with lung involvement in a patient treated with simvastatinA comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapyThe pharmacology of fluvastatin, a new HMG-CoA reductase inhibitorSimvastatin-induced rhabdomyolysisSimvastatin-induced rhabdomyolysis followed by a melas syndromeEffects of Combined Bezafibrate-Simvastatin Appraised in Healthy SubjectsLovastatin-Induced Rhabdomyolysis in the Absence of Concomitant DrugsRhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporineDrugs affecting lipid metabolism 15 February 1991Volume 114, Issue 4Page: 342-342KeywordsAcute renal failureCreatine kinaseDrugsImmunosuppressivesMusclesMyositisNiacinRhabdomyolysis Issue Published: 15 February 1991 PDF downloadLoading ...